Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
waymade healthcare plc - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
zentiva pharma uk ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
a a h pharmaceuticals ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
alliance healthcare (distribution) ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
sigma pharmaceuticals plc - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
arrow generics ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
almus pharmaceuticals ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
milpharm ltd - amisulpride - oral tablet - 200mg
Storbritannia -
engelsk -
MHRA (Medicines & Healthcare Products Regulatory Agency)
amisulpride 200mg tablets
creo pharma ltd - amisulpride - oral tablet - 200mg
Australia -
engelsk -
Department of Health (Therapeutic Goods Administration)
amisulpride 200 winthrop amisulpride 200 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.